The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 29, 2020
Filed:
Jun. 04, 2018
Il-2rβ-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody
Applicant:
Nektar Therapeutics, San Francisco, CA (US);
Inventors:
Murali Krishna Addepalli, Secunderabad, IN;
Deborah H. Charych, Albany, CA (US);
Seema Kantak, Pacifica, CA (US);
Steven Robert Lee, San Lorenzo, CA (US);
Assignee:
Nektar Therapeutics, San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 47/60 (2017.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/2013 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); C07K 16/2815 (2013.01); C07K 16/2818 (2013.01); C07K 16/3015 (2013.01); C07K 16/3046 (2013.01); C07K 16/3084 (2013.01); A61K 2039/505 (2013.01); A61K 2300/00 (2013.01); C07K 2317/76 (2013.01);
Abstract
The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2Rβ-activating amount of a long acting, IL-2Rβ-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.